These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 19956600)

  • 1. Structural diversity of the active N-terminal kinase domain of p90 ribosomal S6 kinase 2.
    Malakhova M; Kurinov I; Liu K; Zheng D; D'Angelo I; Shim JH; Steinman V; Bode AM; Dong Z
    PLoS One; 2009 Nov; 4(11):e8044. PubMed ID: 19956600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural basis for activation of the autoinhibitory C-terminal kinase domain of p90 RSK2.
    Malakhova M; Tereshko V; Lee SY; Yao K; Cho YY; Bode A; Dong Z
    Nat Struct Mol Biol; 2008 Jan; 15(1):112-3. PubMed ID: 18084304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p90 ribosomal S6 kinase 2 is associated with and dephosphorylated by protein phosphatase 2Cdelta.
    Doehn U; Gammeltoft S; Shen SH; Jensen CJ
    Biochem J; 2004 Sep; 382(Pt 2):425-31. PubMed ID: 15206906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of the p90 ribosomal S6 kinase 2 carboxyl-terminal domain as a protein kinase.
    Chrestensen CA; Sturgill TW
    J Biol Chem; 2002 Aug; 277(31):27733-41. PubMed ID: 12016217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The structure of MSK1 reveals a novel autoinhibitory conformation for a dual kinase protein.
    Smith KJ; Carter PS; Bridges A; Horrocks P; Lewis C; Pettman G; Clarke A; Brown M; Hughes J; Wilkinson M; Bax B; Reith A
    Structure; 2004 Jun; 12(6):1067-77. PubMed ID: 15274926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crystal structures of the N-terminal kinase domain of human RSK1 bound to three different ligands: Implications for the design of RSK1 specific inhibitors.
    Ikuta M; Kornienko M; Byrne N; Reid JC; Mizuarai S; Kotani H; Munshi SK
    Protein Sci; 2007 Dec; 16(12):2626-35. PubMed ID: 17965187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phosphoserine-regulated docking site in the protein kinase RSK2 that recruits and activates PDK1.
    Frödin M; Jensen CJ; Merienne K; Gammeltoft S
    EMBO J; 2000 Jun; 19(12):2924-34. PubMed ID: 10856237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A regulatory mechanism for RSK2 NH(2)-terminal kinase activity.
    Cho YY; Yao K; Pugliese A; Malakhova ML; Bode AM; Dong Z
    Cancer Res; 2009 May; 69(10):4398-406. PubMed ID: 19435896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bacterial Expression, Purification and In Vitro Phosphorylation of Full-Length Ribosomal S6 Kinase 2 (RSK2).
    Utepbergenov D; Hennig PM; Derewenda U; Artamonov MV; Somlyo AV; Derewenda ZS
    PLoS One; 2016; 11(10):e0164343. PubMed ID: 27732676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Homology model of RSK2 N-terminal kinase domain, structure-based identification of novel RSK2 inhibitors, and preliminary common pharmacophore.
    Nguyen TL; Gussio R; Smith JA; Lannigan DA; Hecht SM; Scudiero DA; Shoemaker RH; Zaharevitz DW
    Bioorg Med Chem; 2006 Sep; 14(17):6097-105. PubMed ID: 16723234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insights into the inhibition of the p90 ribosomal S6 kinase (RSK) by the flavonol glycoside SL0101 from the 1.5 Å crystal structure of the N-terminal domain of RSK2 with bound inhibitor.
    Utepbergenov D; Derewenda U; Olekhnovich N; Szukalska G; Banerjee B; Hilinski MK; Lannigan DA; Stukenberg PT; Derewenda ZS
    Biochemistry; 2012 Aug; 51(33):6499-510. PubMed ID: 22846040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Computational and Biochemical Discovery of RSK2 as a Novel Target for Epigallocatechin Gallate (EGCG).
    Chen H; Yao K; Chang X; Shim JH; Kim HG; Malakhova M; Kim DJ; Bode AM; Dong Z
    PLoS One; 2015; 10(6):e0130049. PubMed ID: 26083344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation of constitutively active p90 ribosomal S6 kinase in vivo. Implications for the mitogen-activated protein kinase-activated protein kinase family.
    Poteet-Smith CE; Smith JA; Lannigan DA; Freed TA; Sturgill TW
    J Biol Chem; 1999 Aug; 274(32):22135-8. PubMed ID: 10428774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of inhibitors against p90 ribosomal S6 kinase 2 (RSK2) through structure-based virtual screening with the inhibitor-constrained refined homology model.
    Li S; Zhou Y; Lu W; Zhong Y; Song W; Liu K; Huang J; Zhao Z; Xu Y; Liu X; Li H
    J Chem Inf Model; 2011 Nov; 51(11):2939-47. PubMed ID: 21995341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The ribosomal S6 kinase 2 (RSK2)-SPRED2 complex regulates the phosphorylation of RSK substrates and MAPK signaling.
    Lopez J; Bonsor DA; Sale MJ; Urisman A; Mehalko JL; Cabanski-Dunning M; Castel P; Simanshu DK; McCormick F
    J Biol Chem; 2023 Jun; 299(6):104789. PubMed ID: 37149146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exogenously added fibroblast growth factor 2 (FGF-2) to NIH3T3 cells interacts with nuclear ribosomal S6 kinase 2 (RSK2) in a cell cycle-dependent manner.
    Soulet F; Bailly K; Roga S; Lavigne AC; Amalric F; Bouche G
    J Biol Chem; 2005 Jul; 280(27):25604-10. PubMed ID: 15879597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphorylation of p90 ribosomal S6 kinase (RSK) regulates extracellular signal-regulated kinase docking and RSK activity.
    Roux PP; Richards SA; Blenis J
    Mol Cell Biol; 2003 Jul; 23(14):4796-804. PubMed ID: 12832467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of quercitrin as an inhibitor of the p90 S6 ribosomal kinase (RSK): structure of its complex with the N-terminal domain of RSK2 at 1.8 Å resolution.
    Derewenda U; Artamonov M; Szukalska G; Utepbergenov D; Olekhnovich N; Parikh HI; Kellogg GE; Somlyo AV; Derewenda ZS
    Acta Crystallogr D Biol Crystallogr; 2013 Feb; 69(Pt 2):266-75. PubMed ID: 23385462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The crystal structure of the active form of the C-terminal kinase domain of mitogen- and stress-activated protein kinase 1.
    Malakhova M; D'Angelo I; Kim HG; Kurinov I; Bode AM; Dong Z
    J Mol Biol; 2010 May; 399(1):41-52. PubMed ID: 20382163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eriodictyol inhibits RSK2-ATF1 signaling and suppresses EGF-induced neoplastic cell transformation.
    Liu K; Cho YY; Yao K; Nadas J; Kim DJ; Cho EJ; Lee MH; Pugliese A; Zhang J; Bode AM; Dong Z; Dong Z
    J Biol Chem; 2011 Jan; 286(3):2057-66. PubMed ID: 21098035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.